Type your tag names separated by a space and hit enter




Trade Name(s)

  • Fulyzaq

Ther. Class.

Pharm. Class.


Symptomatic relief of non-infectious diarrhea in HIV-infected patients currently receiving antiretroviral therapy.


  • A natural product derived from Croton lechleri, a species of flowering plant.
  • Inhibits cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CTFR) chloride ion channels and the calcium-activated chloride channels on luminal membranes of enterocytes. Blocks chloride secretion and water loss by inhibiting chloride channels on the membranes of enterocytes.

Therapeutic Effect(s):

Decreased incidence and severity of diarrhea.


Absorption: Minimal absorption following oral administration.

Distribution: Unknown.

Metabolism and Excretion: Unknown.

Half-life: Unknown.




Contraindicated in:

  • None noted.

Use Cautiously in:

  • Infectious causes of diarrhea (evaluate and treat prior to use);
  • OB: Use during pregnancy only if clearly needed;
  • Lactation: Breast feeding should be avoided by HIV-infected patients;
  • Pedi: Safe and effective use in children <18 yr has not been established.

Adverse Reactions/Side Effects

CNS: anxiety

EENT: nasopharyngitis

Resp: bronchitis, cough, upper respiratory tract infection

GI: abdominal distention, flatulence, hemorrhoids, nausea, ↑ liver function tests

GU: urinary tract infection

MS: arthralgia, back pain, muscuoloskeletal pain

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Due to minimal systemic absorption, interactions are unlikely.


PO: (Adults) 125 mg twice daily.


Delayed-release tablets: 125 mg


  • Assess for abdominal distention, presence of bowel sounds, and usual pattern of bowel function.
  • Assess color, consistency, and amount of stool produced.

Potential Diagnoses


  • PO: Administer tablets twice daily with or without food. Swallow tablets whole; do not crush, break, or chew.

Patient/Family Teaching

  • Instruct patient to take crofelemer as directed.
  • Advise female patients to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Decreased incidence and severity of diarrhea.

crofelemer is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Nursing Central is the award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Learn more.


Quiring, Courtney, et al. "Crofelemer." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Nursing Central, nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109834/all/crofelemer.
Quiring C, Sanoski CA, Vallerand AH. Crofelemer. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109834/all/crofelemer. Accessed July 23, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Crofelemer. In Davis's Drug Guide. Available from https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109834/all/crofelemer
Quiring C, Sanoski CA, Vallerand AH. Crofelemer [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 July 23]. Available from: https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109834/all/crofelemer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - crofelemer ID - 109834 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/109834/all/crofelemer PB - F.A. Davis Company ET - 16 DB - Nursing Central DP - Unbound Medicine ER -